CorMedix
CRMD
79 hedge funds and large institutions have $77.8M invested in CorMedix in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 10 closing their positions.
122% more call options, than puts
Call options by funds: $2.66M | Put options by funds: $1.2M
43% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 21
0% more funds holding
Funds holding: 79 → 79 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
3.7% less ownership
Funds ownership: 33.56% → 29.86% (-3.7%)
28% less capital invested
Capital invested by funds: $107M → $77.8M (-$29.6M)
Top Buyers
Top Sellers
CRMD Hedge Fund Activity: Q2 2021 in Review
79 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q2 2021, worth a combined $77.8M — down 28% from $107M a quarter earlier.
Fund positioning in CRMD was balanced in Q2 2021: 10 funds opened new positions, 10 closed out, 30 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $1.91M. The largest seller was Maven Securities, exiting entirely with an estimated $1.08M sold.
- 79 institutional investors held CorMedix (CRMD) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $77.8M of CorMedix stock for Q2 2021, down 28% quarter-over-quarter.
- 10 funds opened new CorMedix positions in Q2 2021 and 10 closed out, a net change of 0 holders.
- The largest CorMedix buyer in Q2 2021 was BlackRock, an estimated $1.91M added.
- The largest CorMedix seller in Q2 2021 was Maven Securities, an estimated $1.08M sold.
Based on aggregated 13F filings for Q2 2021.